PRED-G
LOE ApproachingNDAOPHTHALMICOINTMENT
Approved
Dec 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 11h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PRED-G is a small-molecule ophthalmic ointment approved in 1989 for eye-related indications. The exact mechanism of action and pharmacologic class are not publicly disclosed in available data. This is a mature, legacy product in the AbbVie ophthalmology portfolio.
LOE Approaching
Product approaching loss of exclusivity with modest competitive pressure (30% intensity); expect declining team investment and consolidation of marketing roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
PRED-G offers minimal career growth opportunity given zero linked job openings and imminent LOE status. Professionals on this team should prioritize upskilling or lateral moves to higher-growth AbbVie ophthalmology or franchise products to maintain career trajectory.
Brand ManagerField Sales Representative
Worked on PRED-G at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.